Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43384 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Tali Eviatar und 35 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Tel Aviv Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Interleukin 1 Receptor Antagonist Protein, Antibodies, Monoclonal, Hereditary Autoinflammatory Diseases, Antirheumatic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome.
Methods
This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with interleukin‐1 inhibition. Global response (GR) was defined as the absence of inflammatory symptoms and ≥50% decrease in steroid dose and C‐reactive protein. Multiple regression analysis was performed to identify associated variables. Drug survival was analyzed using Kaplan‐Meier plots and log‐rank test, with Cox regression models for associated factors.
Results
We included 47 male patients with VEXAS; 44 received anakinra and 9 received canakinumab, with 6 patients using both at different time points. GR at 1 month was 34% for anakinra and 100% for canakinumab ( P < 0.001) and 22% and 78% at 3 months, respectively ( P = 0.001). Treatment with canakinumab was associated with a higher odds ratio (OR) of achieving GR at 3 months (OR 28.8, 95% confidence interval 3.0–273.9; P = 0.004) in a multivariable analysis. Median drug survival was 54 (interquartile range [IQR] 30–56) months for canakinumab at 300 mg/month compared with 7 (IQR 4–8) months for canakinumab 150 mg/month and 1 (IQR 1–2.5) months for anakinra ( P = 0.01). Injection‐site reactions were only recorded for the anakinra group (47 vs 0%; P = 0.006), whereas infections were more frequent in the anakinra group (31% and 11%; P = 0.3).
Conclusion
Canakinumab demonstrated superior clinical response and drug survival with fewer adverse events compared with anakinra. Monthly canakinumab 300 mg may be considered as an effective steroid‐sparing therapeutic option for patients with VEXAS. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Tel Aviv Medical Center, Tel Aviv, Israel.
- Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.
- Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy.
- Médecine Interne et Polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France.
- Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire d'Angers, Angers, France.
ORCID-Profile: Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Iftach Sagy, Oshrat E Tayer-Shifman, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Karim Sacre, Laurent Arnaud, Ori Elkayam, Jérôme Hadjadj, Arsene Mekinian
Zitieren
APA
Eviatar, T., Capelusnik, D., Campochiaro, C., Lacombe, V., Jachiet, V., Zisapel, M., Sagy, I., Tayer-Shifman, O. E., Ozeri, D., Kivity, S., Tomelleri, A., Terrier, B., Peleg, H., Comont, T., Sacre, K., Woaye-Hune, P., Arnaud, L., Lazaro, E., Grobost, V., …, & Mekinian, A. (2026). Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43384
Vancouver
Eviatar T, Capelusnik D, Campochiaro C, Lacombe V, Jachiet V, Zisapel M, et al. Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study. Arthritis & Rheumatology. 2026. doi:10.1002/art.43384
BibTeX
@article{Eviatar2026,
author = {Eviatar, Tali and Capelusnik, Dafne and Campochiaro, Corrado and Lacombe, Valentin and Jachiet, Vincent and Zisapel, Michael and Sagy, Iftach and Tayer-Shifman, Oshrat E and Ozeri, David and Kivity, Shaye and Tomelleri, Alessandro and Terrier, Benjamin and Peleg, Hagit and Comont, Thibault and Sacre, Karim and Woaye-Hune, Pascal and Arnaud, Laurent and Lazaro, Estibaliz and Grobost, Vincent and Lifermann, Francois and Samson, Maxime and Ardois, Samuel and Garnier, Alice and Maria, Alexandre and Cantagrel, Alain and Meyer, Aurore and Bouaziz, Jean-David and Heiblig, Mael and Dagna, Lorenzo and Diral, Elisa and Kosmider, Olivier and Elkayam, Ori and Hadjadj, Jérôme and Georgin-Lavialle, Sophie and Fain, Olivier and Mekinian, Arsene},
title = {Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43384}
}
EUVIMED